Abstract
Infliximab is a chimeric anti-tumour necrosis factor-alpha antibody that is efficacious in treating Crohn's disease. However, its immunomodulatory properties increase susceptibility to opportunistic infections. We present a case of cutaneous Nocardia infection in a patient who was taking infliximab for Crohn's disease. The case illustrates the challenges in the diagnosis and management of this disease and serves as a reminder of the complications associated with the use of immunomodulatory agents.
MeSH terms
-
Anti-Bacterial Agents / therapeutic use
-
Antibodies, Monoclonal / adverse effects*
-
Antibodies, Monoclonal / therapeutic use
-
Biopsy, Needle
-
Crohn Disease / diagnosis
-
Crohn Disease / drug therapy*
-
Crohn Disease / immunology
-
Drug Therapy, Combination
-
Follow-Up Studies
-
Humans
-
Immunohistochemistry
-
Infliximab
-
Leg Dermatoses / diagnosis
-
Leg Dermatoses / drug therapy
-
Male
-
Middle Aged
-
Nocardia Infections / drug therapy
-
Nocardia Infections / etiology*
-
Opportunistic Infections / diagnosis*
-
Opportunistic Infections / drug therapy
-
Prednisone / adverse effects*
-
Prednisone / therapeutic use
-
Risk Assessment
-
Severity of Illness Index
-
Skin Diseases, Bacterial / drug therapy
-
Skin Diseases, Bacterial / etiology*
-
Skin Diseases, Bacterial / pathology
Substances
-
Anti-Bacterial Agents
-
Antibodies, Monoclonal
-
Infliximab
-
Prednisone